Ngā hua rapu - V.R. Peddi

  • E whakaatu ana i te 1 - 6 hua o te 6
Whakamahine hua
  1. 1
    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus

    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus mā Fuad S. Shihab, Y. Qazi, S. Mulgaonkar, Kevin McCague, Dharmesh Patel, V.R. Peddi, David R. Shaffer

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety

    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety mā Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Graeme R. Russ, Brad A. Marder, C. Hahn, H. Li, Alison Flynn, Sam Schulman

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.

    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft. mā Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Frutuoso, Brad A. Marder, Graeme R. Russ, Alison Flynn, C. Hahn, Michael A. Tortorici, Sam Schulman

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data

    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data mā Yasir Qazi, David R. Shaffer, Bruce Kaplan, D.Y. Kim, Fu L. Luan, V.R. Peddi, Fuad S. Shihab, Stephen J. Tomlanovich, S. Yilmaz, Kevin McCague, Dharmesh Patel, S. Mulgaonkar

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.

    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters. mā Fritz Diekmann, Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Brad A. Marder, G. R. Russ, Alison Flynn, C. Hahn, H. Li, Michael A. Tortorici, Sam Schulman

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients

    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients mā Stéphan Busque, Joseph R. Leventhal, Daniel C. Brennan, Steven Steinberg, Göran B. Klintmalm, T. Shah, S. Mulgaonkar, Jonathan S. Bromberg, F. Vincenti, Sundaram Hariharan, Douglas P. Slakey, V.R. Peddi, Rosemary A. Fisher, Nervin Lawendy, C. Wang, Gordon Chun‐Kau Chan

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: